Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
Salubris Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08
Salubris Biotherapeutics Presents Positive 6-Month Data from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at The Heart Failure Society of America Annual Meeting 2023